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Giardiasis, an intestinal infection caused by Giardia lamblia, was recently included in the ‘Neglected 
Diseases Initiative’ by the World Health Organization. Symptomatic patients can develop mild diarrhea 
up to a severe malabsorption syndrome, and children may show significantly impaired cognitive and 
physical development. Currently, nitroimidazoles are the main class of antibiotic used to treat giardiasis. 
Despite the efficacy of these drugs, adverse effects and reported resistance have increased, encouraging 
studies to identify and develop therapeutic alternatives. In this context, probiotics may represent an 
attractive option. Probiotics are defined as live microorganisms that, when administered in suitable 
amounts, confer a health benefit to the host. The use of probiotics in the treatment of parasitosis has 
been suggested because of its beneficial effects, such as a reduced time of gastrointestinal symptoms and 
parasite load in animal models and humans. Probiotics have been studied as an alternative treatment for 
giardiasis. In this review, we evaluated probiotic effectiveness in the treatment and prevention of this 
disease. Based on the studies examined herein, we conclude that probiotics have a beneficial effect on 
the modulation of giardiasis.
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INTRODUCTION
Giardiasis, an intestinal infection caused by the 
protozoan Giardia lamblia (synonyms - G. intestinalis and 
G. duodenalis), is considered the most common human 
intestinal parasitosis in the world. It is frequent in both 
developed and developing countries, and is estimated to 
inflict 280 million symptomatic human infections annually. 
Due to its clinical and epidemiological importance, in 
2004, the World Health Organization (WHO) included 
giardiasis in the ‘Neglected Diseases Initiative’ (Savioli, 
Smith, Thompson, 2006).
In most cases, infection is asymptomatic, and 
when symptoms occur, the most common manifestations 
are fatigue, anorexia, belching, vomiting, flatulence, 
abdominal pain and distension, and steatorrhea. Such 
clinical conditions establish an intestinal malabsorption 
syndrome that can lead to significant weight loss and 
nutritional deficiencies of the host and, when present in 
children, may lead to severe growth and cognitive deficits 
(Matos et al., 2008).
Among the forms of treatment for giardiasis and 
its symptoms, the use of drugs such as nitroimidazoles, 
nitrofurans as well as phytotherapics are commonly 
highlighted. However, due to an increase in resistance 
to these compounds, there is an urgent call for the 
development of novel therapeutic strategies to fight the 
pathogen in more healthy and effective way. Therefore, 
nutritional interventions and modifications of the intestinal 
microenvironment through probiotic administration 
may be an important therapeutic alternative (Iannitti, 
Palmieri, 2010). In this context, the aim of this revision 
is to demonstrate the role of probiotics in treating and 
preventing clinical and experimental giardiasis. 
Here, we summarize the experimental and clinical 
evidence on probiotics, such as Lactobacillus and 
Saccharomyces boulardii, by providing a comprehensive 
L. L. A. Ventura1, D. R. Oliveira2, M. A. Gomes1, M. R. F. Torres
Braz. J. Pharm. Sci. 2018;54(2):e17360Page 2 / 7
overview of their efficacy as an alternative therapy for 
giardiasis. Studies published between 2000 and 2016 were 
chosen through a systematic search using combinations of 
the keywords ‘Giardia lamblia’, ‘giardiasis’, ‘probiotics’, 
and ‘treatment’ in PubMed and Science Direct electronic 
databases. Clinical and experimental articles that used 
probiotics as therapeutic agents and were written in the 
English language have been included. 
Giardia and giardiasis 
Giardia exists under two distinct life forms: cyst, 
the resistant form, responsible for the transmission of the 
parasite between vertebrate hosts, and trophozoite, the 
vegetative form, that replicates within the intestinal tract 
of the hosts and leads to clinical manifestation. Giardia 
differentiation occurs through the processes of excystation, 
in which the parasite changes from cyst to trophozoite, and 
encystment, when it returns to its resistant form (Lauwaet 
et al., 2007). 
Giardia is transmitted through the fecal-oral route, 
directly - from person to person or indirectly through the 
ingestion of food or water contaminated with cysts. Infection 
is restricted to the intestinal lumen, where trophozoites 
replicate and adhere to the mucosa resulting in enterocytes 
apoptosis, increased intestinal permeability and nutrient 
malabsorption (Solaymani‑Mohammadi, Singer, 2011) 
and, consequently, malnutrition, nutritional deficiencies, 
and cognitive impairment in children and immunodeficient 
adults (Simsek, Yildeiz‑Zeynek, Kurcer, 2004).
The pathophysiology of acute diarrhea in giardiasis 
implicates increased rates of enterocyte apoptosis, 
disruption of the intestinal barrier function, activation 
of host lymphocytes, CD8+ lymphocyte-mediated 
shortening of brush border microvilli with or without 
coinciding villous atrophy, crypt hyperplasia, deficiency 
of disaccharidases, intestinal malabsorption, anion 
hypersecretion, and increased intestinal transit (Müller, 
von Allmen, 2005; Buret et al., 2015).
Both innate and adaptive immunity mechanisms 
are essential for the elimination of the parasite from the 
intestine. Innate immunity mechanisms are the first line 
of defense, and among them are the mucus, peristalsis, 
cytotoxic factors, nitric oxide, microbiota, mast cells, and 
dendritic cells (Lopez-Romero et al., 2015). Mast cells 
have the potential to interfere directly or indirectly in 
the duodenal growth of G. lamblia trophozoites; they are 
essential to control G. lamblia infection, especially due 
to the IL‑6 synthesis. Il‑6 modulates B‑cell maturation 
and the switching to produce IgA, and mediates T-cell 
differentiation (Lopez-Romero et al., 2015; Merluzzi et 
al., 2010). Moreover, mast cell degranulation increases 
smooth muscle contractility and, in synergy with nitric 
oxide, that relaxes smooth muscle and modulates intestinal 
motility, induces peristalsis (Li et al., 2007).
Other defense mechanisms arising from local 
tissue cells are the cytotoxic effect of Paneth cells and its 
secretion of defensins, and an increase on mucin secretion, 
which reduces parasite adhesion to intestinal epithelial 
cells, allowing for the subsequent removal by peristalsis, 
and thereby reducing the intensity of the infection 
(Müller, Allmen, 2005). Most experimental model studies 
suggest that the host’s main defense against Giardia is the 
production of immunoglobulin A (IgA). The mechanisms 
are not well understood, but are likely to involve ‘immune 
exclusion’, immobilization, or detachment of trophozoites 
from the intestinal epithelium or the mucus layer, rather 
than direct killing (Eckmann, 2003).
While intestinal antibodies and, more specifically, 
anti-variant surface protein IgA antibodies were proven 
to be involved in modulating antigenic variation of the 
parasite, the participation of the local antibody response 
in control of the parasite infection is still controversial 
(Müller, von Allmen, 2005).
T cell participation is associated with disease 
progression, since the depletion of CD4+ T cells in animals 
resulted in chronic giardiasis, whereas CD8+ T cells are 
more related to intestinal mucosa tissue damage resulting 
from giardiasis than with controlling the infection (Scott, 
Yu, Buret, 2004). IgA and CD4+ T cells are fundamental 
to the process of Giardia clearance. It has been suggested 
that CD4+ T cells play a double role during the anti-Giardia 
immune response. First, they activate and stimulate the 
differentiation of B cells to generate Giardia-specific 
antibodies. Second, they act through a B-cell-independent 
mechanism that is probably mediated by Th17 cells 
(Lopez-Romero et al., 2015).
Giardia and intestinal microbiome association
It is widely known that the intestinal microbiota 
plays a relevant role in the maintenance of human health. 
This includes impeding colonization by pathogenic agents, 
fermenting non‑soluble fibers, which produce short chain 
fatty acids, and stimulating immune system development 
(Sharma, Young, Neu, 2010). The linkages among the 
human body, gut microbiota, and parasites result in a 
complex ecosystem where alterations in one of these 
components determine a counter response in the others 
(Berrilli et al., 2012).
Torres et al. (2000) showed that Giardia was unable 
to induce disease in germ-free mice. Furthermore, they 
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were the first to demonstrate the stimulatory action of 
a combination of microbial components isolated from 
the dominant duodenal microbiota of children with 
symptomatic giardiasis associated with germ-free mice 
experimentally inoculated with axenic Giardia lamblia. 
Nevertheless, none of the combinations of bacteria were 
able to stimulate the protozoan pathogenicity in germ-free 
mice in the same level as the microbiota of conventional 
mice did. These findings can be explained by smaller 
Peyer’s patches, fewer plasma cells, fewer intraepithelial 
lymphocytes (IELs), impaired antimicrobial peptide 
and IgA secretion, and reduced CD4+ and CD8+ T cell 
numbers found in germ-free mice compared to those in 
conventional mice (Chung et al., 2012).
It has been suggested that the intestinal microbiota 
composition can potentially interfere in the process of G. 
lamblia infection. Findings from ongoing research indicate 
that the post‑infectious effects of giardiasis may be due to 
microbiota dysbiosis induced by the parasite during the 
acute phase of infection (Buret et al., 2015).
Keselman et al. (2016) found that the disruption 
of the intestinal microbiota through antibiotic treatment 
for G. lamblia limited the disaccharidase deficiency, 
prevented pathological CD8+ T cell activation, and also 
did not change the numbers of CD4+ T cells in the lamina 
propria and the activation of T cell receptor-expressing 
intraepithelial lymphocytes (IEL) found in giardiasis. The 
authors have concluded that differences in the intestinal 
microbiota can contribute to differences in immune 
responses and may, therefore, also contribute to differences 
in clinical outcomes.
Benefits of probiotics in giardiasis
Giardia is resistant to most currently available 
drugs (Busatti, Santos, Gomes, 2009). In this sense, 
new treatment alternatives are needed, aiming not only 
efficiency, but also a reduction of side effects and treatment 
resistance.
Probiotics are considered non-pathogenic 
microorganisms (bacteria or yeasts) that, when consumed 
in adequate amounts, produce beneficial effects on the 
health and well-being of the host (Varavallo, Thomé, 
Teshima, 2008). The competition for binding sites and 
available food sources in the intestinal lumen limits 
pathogen survival in this environment (Reid, Hammond, 
2005). The most commonly consumed probiotics 
belong to the genus Lactobacillus and Bifidobacterium. 
Mechanisms by which probiotics might improve host 
health include immune function augmentation through 
reinforcing mucosal barrier function, reducing mucosal 
transfer of luminal organisms and metabolites to the host, 
increasing mucosal antibody production, strengthening 
epithelia integrity and direct antagonism of pathogenic 
microorganisms (Conlon, Bird, 2015). 
Some bacteria genera, such as Lactobacillus and 
Bifidobacterium, have a direct relation with immune 
response stimulation because they enhance IgA production 
and secretion through an alteration of the cytokine milieu 
in the gut mucosa, induce epithelial cell expression 
of TGFβ and IL‑10 as well as IL‑6, which potentiate 
IgA production, and induce/augment the expression 
of polymeric Ig receptors on the basolateral surface of 
intestinal epithelial cells (Hardy et al., 2013).
However, in order for the desired benefits to be 
gained, probiotics must be present in functional foods for 
consumption in adequate amounts. Some studies suggest 
that the effective therapeutic dose for health benefits is 5 
billion colony forming units a day (5 x 109 CFU/day) for 
at least five days (Gupta, Garg, 2009).
Experimental trials with probiotics in giardiasis in 
animal models
Studies involving the action of probiotics as an 
alternative therapy on enteric parasites, such as G. 
lamblia, have been conducted due to their worldwide 
epidemiological importance as well as because of the 
damage caused upon the host. The first report on the in vivo 
effect of Lactobacillus johnsonii La1 against G. lamblia 
(Humen et al., 2005) has demonstrated that animals 
treated with 108 CFU for seven days before trophozoite 
inoculation did not show any morphological damage on 
the intestinal epithelium, and had a reduced proportion of 
active trophozoite and infection length. 
Experimental studies have demonstrated that 
Giardia infection reduced both the severity and duration 
when probiotics (Lactobacillus rhamnosus, Lactobacillus 
casei) were administered prior or simultaneous to the 
parasite. Daily administration of 109 CFU of Lactobacillus 
casei in gerbils for 30 days reduces the proportion of 
active number of trophozoites in the gut and leads to 
the resolution of a Giardia infection within 14 days, and 
protected against parasitic-induced mucosal damage, 
suggesting that probiotics offer a safe and effective 
mode to prevent and treat Giardia infection (Shukla, 
Devi, Sehgal, 2008). Normal microvillus morphology 
and enhanced number of goblet cells were also found in 
probiotic-fed Giardia-infected mice compared to severe 
microvillus atrophy, edematous, vacuolated epithelial 
cells, and ileitis in Giardia-infected mice (Shukla, Sidhu, 
Verma, 2012).
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Goyal, Tiwari, Shukla (2011) compared the 
effectiveness of 4 bacterial strains (Lactobacillus 
rhamnosus GG (LGG), L. acidophilus, L. plantarum and 
L. casei) in the modulation of murine giardiasis. Animals 
received a daily, single strain 109 CFU dose via orogastric 
gavage. LGG has been proven more effective in reducing 
the G. lamblia cycle duration, for its increased rates of cyst 
excretion and reduced the number of active trophozoite in 
the intestine, leading to disease suppression approximately 
13 days after experimental inoculation. 
Recent studies have suggested that probiotics 
have an anti-Giardia effect and modulate the mucosal 
immune response. Goyal, Shukla (2013) showed that 
oral administration of the probiotic LGG (1 x 109 
lactobacilli/0.1 mL) to Giardia-infected mice with 1 x 106 
trophozoites/0.1 mL, restores the normal gut microbiota 
and modulates the mucosal immune response, since a 
significant increase in the levels of cytokines IL‑6 and 
IL‑10, specific secretory IgA antibody, IgA+ cells, and 
CD4+ T lymphocytes were observed in contrast with the 
reduced levels of pro-inflammatory cytokine INF and 
decreased percentage of cytotoxic CD8+ T lymphocytes 
in the lamina propria. Goyal, Rishi, Shulka (2013) also 
showed the antioxidative properties of LGG in Giardia 
mediated tissue injury. Probiotics fed, Giardia-infected 
mice, showed a significant increase in the levels of 
antioxidants (reduced glutathione and superoxide 
dismutase) and intestinal disaccharidases (sucrase and 
lactase) and decreased levels of oxidants in the small 
intestine in comparison with Giardia-infected mice. 
Histopathological findings also revealed an almost normal 
cellular morphology of the small intestine in probiotic-fed 
Giardia-infected mice compared with non-probiotic-fed 
Giardia-infected mice. Fused enterocytes, villous atrophy, 
and increased infiltration of lymphocytes were observed in 
Giardia‑infected mice, thereby suggesting that the effects 
of probiotic LGG are biologically plausible and could be 
used as an alternative microbial interference therapy.
It has been demonstrated the ability of Enterococcus 
faecium SF68 in the improvement of specific anti‑Giardia 
immune response in mice (Benyacoub et al., 2005) This 
improvement was characterized by a progressive increase 
in intestinal IgA and serum IgG levels, and consequent 
decline of the enteric parasitic and antigenic overload. In 
addition, a higher proportion of CD4+ T cells in Peyer’s 
patches and spleen could be observed, suggesting that 
this probiotic might be useful in the treatment of Giardia 
infection.
Shukla, Kaur, Sharma (2013) also demonstrated 
the therapeutic effect of probiotic Lactobacillus casei, 
alone and in conjunction with antiprotozoal drugs like 
albendazole, tinidazole, metronidazole, and nitazoxanide, 
on the outcome of giardiasis in murine model. The co-
administration of the probiotic and albendazole reduced 
both the excretion of Giardia cysts in feces and trophozoite 
counts in the intestinal fluid, and restored villi and crypts to 
normal morphology. The authors suggested that probiotics 
and antiprotozoal drugs in combination can be a more 
effective therapy for improved treatment and enhanced 
recovery from gastrointestinal diseases.
Other authors evaluated the ability of kefir-
fermented milk, composed mainly of bacteria and yeasts in 
a complex symbiotic association, to protect mice from G. 
lamblia infection. They found that feeding mice with kefir 
reduces infection and promotes the activation of different 
mechanisms of humoral and cellular immunity that are 
downregulated by parasitic infection, thus contributing 
to protection (Franco et al., 2013).
Amer, Mossallan, Mahrous (2014) evaluated the 
therapeutic efficacy of bacteriocins derived from newly 
isolated Egyptian strains of probiotics Lactobacilli 
[L. acidophilus (P106) and L. plantarum (P164)] against 
G. lamblia, both in vitro and in vivo. In vitro results 
showed that 50 µg of L. acidophilus bacteriocin reduced 
the adherence and the number of trophozoites by 58.3 ± 
4.04%. Oral inoculation of 50 µg/mouse L. acidophilus 
bacteriocin for 5 successive days reduced the intestinal 
parasite density, and ameliorated intestinal pathology of 
infected mice. The authors concluded that L. acidophilus 
(P106) derived bacteriocin should be a great promise 
as a potential therapeutic safe alternative to existing 
commercial drugs.
Clinical trials with probiotics in gastrointestinal 
diseases
The current literature offers few studies about the 
use of probiotics as an alternative therapy for giardiasis. 
However, it is possible to find a greater amount of 
studies that highlight the benefits of ingesting such 
microorganisms for the treatment of some enteric diseases 
with similar symptoms to the ones caused by G. lamblia 
infection, particularly diarrhea.
The use of a probiotic cannot ignore the knowledge 
of the genus and species of the strain. In pediatric 
patients, their role for treating acute viral gastroenteritis 
and preventing antibiotic-associated diarrhea in healthy 
children has been demonstrated (Cardile et al., 2016). 
The risk of infection associated with the use of probiotics 
is relatively low; however, there are selected groups of 
patients in who they should be used with caution (Olveira, 
Gonzalez‑Molero, 2016).
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Mansour-Ghanaei et al. (2003) studied patients with 
acute diarrhea caused by amebiasis, which were treated 
with antibiotics associated with a 250 mg of S. boulardii 
orally, thrice a day, for 10 days. This joint administration 
significantly reduced the symptoms’ duration and the 
number of excreted cysts after four weeks. This was 
associated with the yeast’s great potential to restore 
beneficial effects from the normal intestinal microbiota, 
although the precise mechanism of action has not been 
elucidated. 
Regarding the beneficial action of S. boulardii 
associated with antibiotic therapy, Besirbellioglu et al. 
(2006) have shown yeast’s efficiency as an adjunctive 
therapy on adult patients infected with G. lamblia and 
treated with metronidazole 750 mg, 3 times daily, along 
with probiotic dosage of 250 mg, administered twice daily, 
for 10 days. Authors has hypothesized that this yeast exerts 
a trophic effect in the small intestine, increases levels of 
enteric disaccharidases, stimulates intestinal immune 
system, and changes intestinal enzyme activation.
Working with children who had persistent diarrhea, 
Gaon et al., (2003) showed that the administration of S. 
boulardii as well as combined administration of different 
L. casei strains with L. acidophillus (Cerela strain) 
significantly reduced length and frequency of diarrhea and 
gastrointestinal symptoms such as vomiting, abdominal 
distention, and colic at any time during the treatment 
period. Both treatments administered 1010 to 1012 CFU/g of 
probiotic in a 175g of diet, twice a day, for a 5‑day period. 
Patel, DuPont (2015) showed that prebiotics, 
probiotics, and symbiotics are appealing as preventive 
and therapeutic agents for human medical disorders. 
Their efficacy depends on the etiology of the disease and 
the probiotic strain. Restoring the balance of intestinal 
flora by introducing probiotics for disease prevention and 
treatment could be beneficial to human health.
CONCLUSIONS
Probiotics have a positive action in the treatment of 
enteric parasite infections, and this benefit may be due to 
several factors, such as change of intestinal microbiota 
composition, modulation of immune response, and 
reduction of host-pathogen interactions. However, the 
exact mechanism by which probiotics modulate Giardia 
infection requires thorough investigation. We also strongly 
support more research on the best probiotic or probiotic 
association to use in giardiasis. 
REFERENCES
Amer EI, Mossallam SF, Mahrous H. Therapeutic enhancement 
of newly derived bacteriocins against Giardia lamblia. Exp 
Parasitol. 2014;146:52‑63. 
Benyacoub J, Pérez PF, Rochat F, Saudan KY, Reuteler G, Antille 
N, Humen M, De Antoni GL, Cavadini C, Blum S, Schiffrin EJ. 
Enterococcus faecium SF68 enhances the immune response to 
Giardia intestinalis in mice. J Nutr. 2005;135(5):1171‑1176. 
Berrilli F, Di Cave D, Cavallero S, D’amelio S. Interactions 
between parasites and microbial communities in the human gut. 
Front Cell Infect Microbiol. 2012;2:141.
Besirbellioglu BA, Ulcay A, Can M, Erlen, H, Tanyuksel, M, 
Avci, I Araz E, Pahsa A. Saccharomyces boulardii and infection 
due to Giardia lamblia. Scand J Infect Dis. 2006;38(6‑7):479‑481.
Buret GA, Amat CB, Manko A, Beatty JK, Halliez MCM, 
Bhargava A, Motta J P, Cotton J. Giardia duodenalis: New 
research developments in pathophysiology, pathogenesis, and 
virulence factors. Curr Trop Med Rep. 2015;2(3):110‑118.
Busatti H, Santos JFG, Gomes MA. The old and new therapeutic 
approaches to the treatment of Giardiasis: Where are we? Biol 
Targets Ther. 2009;3:273‑87.
Cardile S, Alterio T, Arrigo T, Salpietro C. Role of prebiotics 
and probiotics in pediatric diseases. Minerva Pediatr. 
2016;68(6):487‑497.
Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, 
et al. Gut immune maturation depends on colonization with a 
host‑specific microbiota. Cell. 2012;149(7):1578‑1593.
Conlon MA, Bird AR. The impact of diet and lifestyle on gut 
microbiota and human health. Nutrients. 2015;7(1): 17‑44. 
Eckmann L. Mucosal defenses against Giardia. Parasite 
Immunol. 2003;25(5):259‑270.
Franco Mc, Golowczyc Ma, De Antoni Gl, Pérez Pf, Humen M, 
Serradell M L. Administration of kefir‑fermented milk protects 
mice against Giardia intestinalis infection. J Med Microbiol. 
2013;62(12):1815‑22.
Gaon D, Garcia H, Winter L, Rodriguez N, Quintas R, Gonzalez 
SN, Oliver G. Effect of Lactobacillus strains and Saccharomyces 
boulardii on persistent diarrhea in children. Medicina (B Aires). 
2003;63(4):293‑298.
L. L. A. Ventura1, D. R. Oliveira2, M. A. Gomes1, M. R. F. Torres
Braz. J. Pharm. Sci. 2018;54(2):e17360Page 6 / 7
Goyal N, Rishi P, Shukla G. Lactobacillus rhamnosus GG 
antagonizes Giardia intestinalis induced oxidative stress and 
intestinal disaccharidases: an experimental study. World J 
Microbiol Biotechnol. 2013;29(6):1049‑1057.
Goyal N, Shukla G. Probiotic Lactobacillus rhamnosus GG 
modulates the mucosal immune response in Giardia intestinalis 
- infected BALB/c mice. Dig Dis Sci. 2013;58(5):1218‑1225.
Goyal N, Tiwari RP, Shukla G. Lactobacillus rhamnosus GG as 
an effective probiotic for murine Giardiasis. Interdiscip Perspect 
Infect Dis. 2011;2011:795219.
Gupta V, Garg R. Probiotics. Indian J Med Microbiol. 
2009;27(3):202‑209.
Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, 
prebiotics and immunomodulation of gut mucosal defenses: 
homeostasis and immunopathology. Nutrients. 2013;5(6):1869‑
1912.
Humen MA, De Antoni GL, Benyacoub J, Costas ME, Cardozo 
MI, Kozubsky L, et al. Lactobacillus johnsonii La1 antagonizes 
Giardia intestinalis in vivo. Infect Immun. 2005;73(2):1265‑
1269.
Iannitti T, Palmieri B. Therapeutical use of probiotic formulations 
in clinical practice. Clin Nutr. 2010;29(6):701‑725.
Keselman A, Li E, Maloney J, Singer Sm. The Microbiota 
Contributes to CD8+ T cell activation and nutrient malabsorption 
following intestinal infection with Giardia duodenalis. Infection 
Imunn. 2016;84(10):2853‑2860.
Lauwaet T, Davids BJ, Reiner DS, Gillin FD. Encystation 
of Giardia lamblia: A model for other parasites. Curr Opin 
Microbiol. 2007;10(6):554‑559.
Li E, Zhao A, Shea-Donohue T, Singer SM. Mast cell-mediated 
changes in smooth muscle contractility during mouse Giardiasis. 
Infect Immun. 2007;75(9):4514‑ 4518.
Lopez-Romero G, Quintero J, Astiazarán-García H, Velazquez 
C. Host defences against Giardia lamblia. Parasite Immunol. 
2015;37(8):394‑406.
Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A. 
Efficacy of Saccharomyces boulardii with antibiotics in acute 
amoebiasis. World J Gastroenterol. 2003;9(8):1832‑1833. 
Matos SM, Assis AM, Prado MDA S, Strina A, Santos LA, 
Jesus SR, Barreto ML. Giardia duodenalis infection and 
anthropometric status in preschoolers in Salvador, Bahia State, 
Brazil. Cad Saúde Públ. 2008;24(7):1527‑1535.
Merluzzi S, Frossi B, Gri G, Parusso S, Tripodo C, Pucillo C. 
Mast cells enhance proliferation of B-lymphocytes and drive 
their differentiation toward IgA secreting plasma cells. Blood. 
2010;115(14):2810‑2817.
Müller N, Von Allmen N. Recent insights into the mucosal 
reactions associated with Giardia lamblia infections. Int J 
Parasitol. 2005;35(13):1339‑1347.
Olveira G, González-Molero I. An update on probiotics, 
prebiotics and symbiotics in clinical nutrition. Endocrinol Nutr. 
2016;63(9):482‑494.
Patel R, Dupont HL. New approaches for bacteriotherapy: 
prebiotics, new‑generation probiotics, and symbiotics. Clin 
Infect Dis. 2015;60(Suppl 2):S108‑121.
Reid G, Hammond JA. Probiotics. Some evidence of their 
effectiveness. Can Fam Physic. 2005;51(11):1487‑1493.
Savioli L, Smith H, Thompson A. Giardia and Cryptosporidium 
join the ‘Neglected Diseases Initiative’. Trends Parasitol. 
2006;22(5):203‑208.
Scott KG, Yu LC, Buret AG. Role of CD8+ and CD4+ T 
lymphocytes in jejunal mucosal injury during murine Giardiasis. 
Infect Immun. 2004;72(6):3536‑3542.
Sharma R, Young C, Neu J. Molecular modulation of intestinal 
epithelial barrier: contribution of microbiota. J Biomed 
Biotechnol. 2010;2010:305879. 
Shukla G, Devi P, Sehgal R. Effect of Lactobacillus casei 
as a probiotic on modulation of Giardiasis. Dig Dis Sci. 
2008;53(10):2671‑2679.
Shukla G, Kaur H, Sharma L. Comparative therapeutic effect 
of probiotic Lactobacillus casei alone and in conjunction 
with antiprotozoal drugs in murine Giardiasis. Parasitol Res. 
2013;112(6):2143‑2149.
Shukla G, Sidhu RK, Verma A. Restoration of anthropometric, 
biochemical and histopathological alterations by Lactobacillus 
casei supplementation in Giardia intestinalis infected 
renourished BALB/c mice. Antonie Van Leeuwenhoek. 
2012;102(1):61‑72.
Effect of probiotics on giardiasis. Where are we?
Braz. J. Pharm. Sci. 2018;54(2):e17360 Page 7 / 7
Simsek Z, Yildeiz-Zeynek F, Kurcer MA. Effect of Giardia 
infection on growth and psychomotor development of children 
aged 0–5 years. J Trop Pediatr. 2004;50(2):90‑93.
Solaymani-Mohammadi S, Singer SM. Host immunity and 
pathogen strain contribute to intestinal disaccharidase impairment 
following gut infection. J Immunol. 2011;187(7):3769‑3775.
Torres, MF, Uetanabaro AP, Costa Af, Alves, CA, Farias, LM, 
Bambirra, EA, Nicoli, J. Influence of bacteria from the duodenal 
microbiota of patients with symptomatic Giardiasis on the 
pathogenicity of Giardia duodenalis in gnotoxenic mice. J Med 
Microbiol. 2000;49(3):209‑215.
Varavallo MA, Thomé JN, Teshima E. Aplicação de 
bactérias probióticas para profilaxia e tratamento de doenças 
gastrointestinais. Semina Ciênc Biol Saúde. 2008;29(1):83‑104.
Received for publication on 21st June 2017
Accepted for publication on 29th November 2017
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
